Ontology highlight
ABSTRACT:
SUBMITTER: Shibata N
PROVIDER: S-EPMC6131351 | biostudies-other | 2018 Sep
REPOSITORIES: biostudies-other
Shibata Norihito N Shimokawa Kenichiro K Nagai Katsunori K Ohoka Nobumichi N Hattori Takayuki T Miyamoto Naoki N Ujikawa Osamu O Sameshima Tomoya T Nara Hiroshi H Cho Nobuo N Naito Mikihiko M
Scientific reports 20180910 1
Chronic myelogenous leukemia (CML) is characterized by the oncogenic fusion protein, BCR-ABL protein kinase, against which clinically useful inhibitors have been developed. An alternative approach to treat CML is to degrade the BCR-ABL protein. Recently, potent degraders against BCR-ABL have been developed by conjugating dasatinib to ligands for E3 ubiquitin ligases. Since the degraders contain the dasatinib moiety, they also inhibit BCR-ABL kinase activity, which complicates our understanding o ...[more]